Vimarsana
Biggest News Aggregation in the World

Page 28 - Immune Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immune Sciences Today - Breaking & Trending Today

Alpine Immune Sciences (NASDAQ:ALPN) Issues Quarterly Earnings Results - Vimarsana News

Alpine Immune Sciences (NASDAQ:ALPN) Issues Quarterly Earnings Results

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative net margin of 214.70% and a negative return on equity of 59.07%. […]

Alpine Immune Sciences (NASDAQ:ALPN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - Vimarsana News

Alpine Immune Sciences (NASDAQ:ALPN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ […]

Alpine Immune Sciences (NASDAQ:ALPN) Issues Earnings Results, Misses Estimates By $0.06 EPS - Vimarsana News

Alpine Immune Sciences (NASDAQ:ALPN) Issues Earnings Results, Misses Estimates By $0.06 EPS

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ:ALPN […]

Critical Comparison: Alpine Immune Sciences (NASDAQ:ALPN) vs. Cerevel Therapeutics (NASDAQ:CERE) - Vimarsana News

Critical Comparison: Alpine Immune Sciences (NASDAQ:ALPN) vs. Cerevel Therapeutics (NASDAQ:CERE)

Cerevel Therapeutics (NASDAQ:CERE – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations. Institutional and Insider Ownership 77.0% of Alpine Immune Sciences […]

Zacks: Analysts Anticipate Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Will Post Quarterly Sales of $13.35 Million - Vimarsana News

Zacks: Analysts Anticipate Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Will Post Quarterly Sales of $13.35 Million

Wall Street analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) will post sales of $13.35 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings, with estimates ranging from $5.93 million to $20.00 million. Alpine Immune Sciences posted sales of $3.20 million in […]